LifeMD, Inc.

Equities

LFMD

US53216B1044

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
7.95 ^USD	-3.28%		-6.47%	-4.10%

Jun. 05	KeyBanc Initiates LifeMD at Overweight With $12 Price Target, Cites 'Strong Top & Bottom-Line Growth'	MT
May. 09	Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating	MT

LifeMD, Inc. Provides Revenue Guidance for the Year 2021

November 10, 2021 at 04:05 pm EST

LifeMD, Inc. provided revenue guidance for the year 2021. For the year, the company expects revenue to total between $90 million and $100 million, which would represent growth of between 141% and 168% over the prior year.

Latest news about LifeMD, Inc.

KeyBanc Initiates LifeMD at Overweight With $12 Price Target, Cites 'Strong Top & Bottom-Line Growth'	Jun. 05	MT
Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating	May. 09	MT
LifeMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Transcript : LifeMD, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Earnings Flash (LFMD) LIFEMD Reports Q1 Revenue $44.1M, vs. Street Est of $42.6M	May. 08	MT
Earnings Flash (LFMD) LIFEMD Posts Q1 EPS $0.01, vs. Street Est of $-0.01	May. 08	MT
LifeMD, Inc. Provides Financial Guidance for the Second Quarter of 2024	May. 08	CI
LifeMD, Inc. Revises Financial Guidance for the Full Year of 2024	May. 08	CI
LifeMD, Inc. Announces A New Strategic Partnership Designed to Revolutionize Weight Management Patient Care	May. 02	CI
LifeMD, Inc. Appoints Calum Macrae to Its Board of Directors	Apr. 29	CI
BTIG Adjusts LifeMD's Price Target to $14 From $13, Keeps Buy Rating	Apr. 23	MT
Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating	Mar. 12	MT
Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating	Mar. 12	MT
B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating	Mar. 12	MT
LifeMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Transcript : LifeMD, Inc., Q4 2023 Earnings Call, Mar 11, 2024	Mar. 11
Earnings Flash (LFMD) LIFEMD Reports Q4 Revenue $44.9M, vs. Street Est of $40.5M	Mar. 11	MT
Earnings Flash (LFMD) LIFEMD Posts Q4 EPS $0.15, vs. Street Est of $0.03	Mar. 11	MT
LifeMD, Inc. Provides Earnings Guidance for the First Quarter of 2024 and Revises Earnings Guidance for the Full Year of 2024	Mar. 11	CI
HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating	Jan. 11	MT
LifeMD Provides 2024 Financial Guidance	Jan. 08	RE
LifeMD, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Jan. 08	CI
WeightWatchers Stock Drops 12% After Eli Lilly Launches DTC Weight-Loss Drug Service	Jan. 04	DJ
Medifast, LifeMD Collaborate to Offer Weight Management Solution; Medifast Scraps Quarterly Dividend	Dec. 13	MT
Transcript : LifeMD, Inc., Medifast, Inc. - Special Call	Dec. 13

Chart LifeMD, Inc.

Duration

Period

More charts

Company Profile

LifeMD, Inc. is a direct-to-patient telehealth company, which provides comprehensive virtual and in-home healthcare. The Company operates through two segments: Telehealth and WorkSimpli. Telehealth segment is engaged in telehealth platform, which integrates a clinician-centric electronic medical record (EMR) system, algorithms for case-load balancing and scheduling, customer relationship management functionality, asynchronous communication, secure synchronous, cloud pharmacy and more. Its technology platform, combined with its 50-state affiliated provider network, enables the management of virtual treatment offerings across various health conditions, including, dermatology, urgent and primary care, chronic care management, dermatology, chronic care management and other. Its WorkSimpli segment offers workplace and document services. This segment offers PDFSimpli an online software as a service platform that allows users to create, edit, convert, sign and share PDF documents.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for LifeMD, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.95 USD

Average target price

12.83 USD

Spread / Average Target

+61.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
LIFEMD, INC.	-4.10%	336M
VEEVA SYSTEMS INC.	-3.90%	29.91B
PRO MEDICUS LIMITED	+31.11%	8.52B
SECTRA AB	+26.15%	4.21B
EVOLENT HEALTH, INC.	-29.31%	2.68B
VERADIGM INC.	-9.44%	1.6B
OMNICELL, INC.	-20.44%	1.37B
LUNIT INC.	-34.19%	1.14B
SIMULATIONS PLUS, INC.	+4.92%	938M
B-SOFT CO.,LTD.	-43.66%	787M

Medical Software & Technology Services